YD Bio (NASDAQ:YDES) Stock Price Down 8.5% – Here’s What Happened

YD Bio Limited (NASDAQ:YDES) fell 8.5% during mid-day trading on Tuesday . The company traded as low as $8.79 and last traded at $9.00. 16,925 shares were traded during trading, a decline of 68% from the average session volume of 53,629 shares. The stock had previously closed at $9.84.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on YDES shares. Wall Street Zen raised shares of YD Bio to a “sell” rating in a report on Tuesday, November 4th. Weiss Ratings reiterated a “sell (d+)” rating on shares of YD Bio in a research note on Monday, December 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

YD Bio Trading Down 11.8%

Hedge Funds Weigh In On YD Bio

A hedge fund recently raised its stake in YD Bio stock. Geode Capital Management LLC grew its holdings in YD Bio Limited (NASDAQ:YDES) by 10.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 58,363 shares of the biotechnology company’s stock after buying an additional 5,292 shares during the quarter. Geode Capital Management LLC owned about 0.08% of YD Bio worth $711,000 at the end of the most recent quarter.

About YD Bio

YD Bio Limited is a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations.